Skip to main content

Advertisement

SpringerLink
Log in

Follow-up of percutaneous microwave (MW) ablation of hepatic lesion: predictive value of CT at 24-h compared with CT at 1 month

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

To retrospectively assess the predictive value of the CT performed at 24 h, compared with the CT performed at 1 month, in the evaluation of the technical success of microwave (MW) ablation of hepatic lesions. In a single center, 50 patients with HCC underwent percutaneous MW ablation between November 2016 and March 2019. Each patient underwent a contrast-enhanced CT exam at 24 h and at 1 month after the procedure. For each patient, was assessed the presence or absence of residual disease, the appearance of a new lesion, complications, and the involvement of the hepatic capsule, both at 24-h and at 1 month. Overall correlation between residual disease, appearance of a new nodule and complications was also assessed. A total of 50 hepatic lesions were treated with US-guided MW ablation. Patients’ mean age was 70.9 years (range 28–87 years). Mean nodule diameter was 17.6 mm (range 7–35 mm). Contingency tables and the χ2 test showed a strong association when looking at capsule involvement (accuracy: 100%), residual disease (accuracy: 90%; p-value 0.003), and the appearance of a new HCC nodule (accuracy: 88%; p-value 0.007); regarding complications, the accuracy was 78% (p-value 0.014). Optimal correlation was reached in 62% of cases, moderate correlation in 26%, minimum correlation in 10% of cases; no cases of zero correlation were recorded. CT at 24 h and 1 month showed comparable efficacy in evaluating residual disease after MW thermal ablation of liver lesions. However, further studies are needed to assess which factors may cause false-negative results at the 24-h CT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019.

    Article  Google Scholar 

  2. Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: from clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274. https://doi.org/10.4254/wjh.v7.i20.2274.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, Kemeny NE, D’Angelica M, Kingham PT, Solomon SB, Sofocleous CT. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29:268–275.e1. https://doi.org/10.1016/j.jvir.2017.08.021.

    Article  PubMed  Google Scholar 

  4. Arora A, Kumar A. Treatment response evaluation and follow-up in hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S126–S129129. https://doi.org/10.1016/j.jceh.2014.05.005.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical Management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–30. https://doi.org/10.1016/S0168-8278(01)00130-1.

    Article  CAS  PubMed  Google Scholar 

  6. Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res. 2013;19:1312–4. https://doi.org/10.1158/1078-0432.CCR-12-3796.

    Article  PubMed  Google Scholar 

  7. Smith TJ. Breast cancer surveillance guidelines. J Oncol Pract. 2013;9:65–7. https://doi.org/10.1200/JOP.2012.000787.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lieng H, Warde P, Bedard P, Hamilton RJ, Hansen AR, Jewett MAS, O’malley M, Sweet J, Chung P. Recommendations for followup of stage I and II seminoma: the Princess Margaret Cancer Centre approach. Can Urol Assoc J. 2018;12:59–66. https://doi.org/10.5489/cuaj.4531.

    Article  PubMed  Google Scholar 

  9. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:871–3. https://doi.org/10.1093/annonc/mdy510.

    Article  PubMed  Google Scholar 

  10. Crocetti L, De Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33:11–7. https://doi.org/10.1007/s00270-009-9736-y.

    Article  PubMed  Google Scholar 

  11. Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Daniele Pinna A, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013;45:712–23. https://doi.org/10.1016/j.dld.2013.01.012.

    Article  PubMed  Google Scholar 

  12. D. NCI, NIH (2009) Common terminology criteria for adverse events v4.0. NIH Publ. pp 0–71

  13. Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6. https://doi.org/10.1007/s00270-017-1703-4.

    Article  CAS  PubMed  Google Scholar 

  14. Boas FE, Do B, Louie JD, Kothary N, Hwang GL, Kuo WT, Hovsepian DM, Kantrowitz M, Sze DY. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26:69–73. https://doi.org/10.1016/j.jvir.2014.09.013.

    Article  PubMed  Google Scholar 

  15. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–7. https://doi.org/10.1016/J.JHEP.2010.03.010.

    Article  PubMed  Google Scholar 

  16. Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang H-J, Lee J-H, Lim JH, Choo IW. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221:447–54. https://doi.org/10.1148/radiol.2212010446.

    Article  CAS  PubMed  Google Scholar 

  17. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transpl. 2009;9:1920–8. https://doi.org/10.1111/j.1600-6143.2009.02695.x.

    Article  CAS  Google Scholar 

  18. Liu W, Zheng Y, Zou R, Shen J, He W, Yang Z, Zhang Y, Li B, Yuan Y. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer. 2018;18:1–9. https://doi.org/10.1186/s12885-018-5069-z.

    Article  Google Scholar 

  19. Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. Am J Roentgenol. 2013;201:80–96. https://doi.org/10.2214/AJR.13.10706.

    Article  Google Scholar 

  20. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG, Solbiati L, Vogl TJ, Wood BJ, Vedantham S, Sacks D. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20:S377–S390390. https://doi.org/10.1016/j.jvir.2009.04.011.

    Article  PubMed  Google Scholar 

  21. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80. https://doi.org/10.1002/hep.29086.

    Article  PubMed  Google Scholar 

  22. Benson AB, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey J-N, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Cancer Netw. 2017;15:563–73. https://doi.org/10.6004/jnccn.2017.0059.

    Article  Google Scholar 

  23. Puijk RS, Ruarus AH, Scheffer HJ, Vroomen LGPH, van Tilborg AAJM, de Vries JJJ, Berger FH, van den Tol PMP, Meijerink MR. Percutaneous liver tumour ablation: image guidance, endpoint assessment, and quality control. Can Assoc Radiol J. 2018;69:51–62. https://doi.org/10.1016/j.carj.2017.11.001.

    Article  PubMed  Google Scholar 

  24. Liang P, Yu J, De Lu M, Dong BW, Yu XL, Zhou XD, Hu B, Xie MX, Cheng W, He W, Jia JW, Lu GR. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol. 2013;19:5430–8. https://doi.org/10.3748/wjg.v19.i33.5430.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Patel N, King AJ, Breen DJ. Imaging appearances at follow-up after image-guided solid-organ abdominal tumour ablation. Clin Radiol. 2017;72:680–90. https://doi.org/10.1016/j.crad.2017.01.014.

    Article  CAS  PubMed  Google Scholar 

  26. Venkatesan AM, Gervais DA, Mueller PR. Percutaneous radiofrequency thermal ablation of primary and metastatic hepatic tumors: current concepts and review of the literature. Semin Intervent Radiol. 2006;23:73–84. https://doi.org/10.1055/s-2006-939843.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Rhim H, Goldberg SN, Dodd GD, Solbiati L, Lim HK, Tonolini M, Cho OK. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. RadioGraphics. 2001;21:S17–S35. https://doi.org/10.1148/radiographics.21.suppl_1.g01oc11s17.

    Article  PubMed  Google Scholar 

  28. Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology. 1998;45(Suppl 3):1214–20.

    PubMed  Google Scholar 

  29. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, Rigamonti A, Barbara C, Grigioni W, Mazziotti A, Bolondi L. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132–7. https://doi.org/10.1002/hep.1840160122.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Postgraduation School in Radiodiagnostic, Università degli Studi di Milano, Facoltà di Medicina e Chirurgia, Via Festa del Perdono 7, 20122, Milan, Italy

    Enrico Maria Fumarola, Pierpaolo Biondetti, Anna Paola Savoldi, Pasquale Grillo & Giovanna Gorga

  2. Department of Diagnostic and Interventional Radiology, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan University, Milan, Italy

    Anna Maria Ierardi

  3. Postgraduation School in Radiodiagnostic, Uninsubria, Facoltà di Medicina e Chirurgia, Varèse, Italy

    Andrea Coppola

  4. Department of Radiology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano, Milan, Italy

    Gianpaolo Carrafiello

  5. ASST Santi Paolo e Carlo, San Paolo Hospital, Milan University, Milan, Italy

    Enrico Maria Fumarola

Authors
  1. Enrico Maria Fumarola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Maria Ierardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierpaolo Biondetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Paola Savoldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pasquale Grillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanna Gorga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Coppola
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gianpaolo Carrafiello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Enrico Maria Fumarola.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fumarola, E.M., Ierardi, A.M., Biondetti, P. et al. Follow-up of percutaneous microwave (MW) ablation of hepatic lesion: predictive value of CT at 24-h compared with CT at 1 month. Med Oncol 37, 41 (2020). https://doi.org/10.1007/s12032-020-01364-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-020-01364-y

Keywords

Search

Navigation